Factors Associated With Short-term Relapse in Patients With Pemphigus Who Receive Rituximab as First-line Therapy - Archive ouverte HAL Access content directly
Journal Articles JAMA Dermatology Year : 2020

Factors Associated With Short-term Relapse in Patients With Pemphigus Who Receive Rituximab as First-line Therapy

, , , , , , , , , , , , , , , (1, 2) , , , , , , , , , , , , , , , , , , , , ,
1
2
Claire Mignard
  • Function : Author
  • PersonId : 1117137
Maud Maho-Vaillant
Marie-Laure Golinski
Pierre Balayé
  • Function : Author
Catherine Prost-Squarcioni
  • Function : Author
Estelle Houivet
  • Function : Author
Sé´bastien Calbo
  • Function : Author
Bruno Labeille
  • Function : Author
Catherine Picard-Dahan
  • Function : Author
Maria Polina Konstantinou
  • Function : Author
Guillaume Chaby
  • Function : Author
Marie-Aleth Richard
Jean-David Bouaziz
Sophie Duvert-Lehembre
  • Function : Author
Emmanuel Delaporte
  • Function : Author
Frédéric Caux
  • Function : Author
Marina Alexandre
  • Function : Author
Saskia Ingen-Housz-Oro
  • Function : Author
Pierre Vabres
Gaëlle Quereux
  • Function : Author
Alain Dupuy
  • Function : Author
Sébastien Debarbieux
  • Function : Author
Martine Avenel-Audran
  • Function : Author
Michel D’incan
Christophe Bédane
  • Function : Author
Nathalie Bénéton
  • Function : Author
Denis Jullien
  • Function : Author
Nicolas Dupin
  • Function : Author
Laurent Misery
Laurent Machet
Marie Beylot-Barry
Olivier Dereure
Bruno Sassolas
  • Function : Author
Jacques Benichou
  • Function : Author
Pascal Joly
  • Function : Author
Vivien Hébert
  • Function : Author

Abstract

; for the French Study Group on Autoimmune Bullous Skin Diseases IMPORTANCE Rituximab and short-term corticosteroid therapy are the criterion standard treatments for patients with newly diagnosed moderate to severe pemphigus. OBJECTIVE To examine factors associated with short-term relapse in patients with pemphigus treated with rituximab. DESIGN, SETTING, AND PARTICIPANTS This post hoc analysis of a randomized clinical trial (Comparison Between Rituximab Treatment and Oral Corticosteroid Treatment in Patients With Pemphigus [RITUX 3]) conducted from January 1, 2010, to December 31, 2015, included patients from 20 dermatology departments of tertiary care centers in France from the RITUX 3 trial and 3 newly diagnosed patients treated according to the trial protocol. Data analysis was performed from February 1 to June 30, 2019. EXPOSURE Patients randomly assigned to the rituximab group in the RITUX 3 trial and the 3 additional patients were treated with 1000 mg of intravenous rituximab on days 0 and 14 and 500 mg at months 12 and 18 combined with a short-term prednisone regimen. MAIN OUTCOMES AND MEASURES Baseline (pretreatment) clinical and biological characteristics (Pemphigus Disease Area Index [PDAI] score, ranging from 0-250 points, with higher values indicating more severe disease) and changes in anti-desmoglein (DSG) 1 and anti-DSG3 values as measured by enzyme-linked immunosorbent assay during the 3 months after rituximab treatment were compared between patients with disease relapse and those who maintained clinical remission during the first 12 months after treatment. The positive and negative predictive values of these factors were calculated. RESULTS Among 47 patients (mean [SD] age, 54.3 [17.0] years; 17 [36%] male and 30 [64%] female) included in the study, the mean (SD) baseline PDAI score for patients with relapsing disease was higher than that of the patients with nonrelapsing disease (54 [33] vs 28 [24]; P = .03). At month 3, 7 of 11 patients with relapsing disease (64%) vs 7 of 36 patients with nonrelapsing disease (19%) had persistent anti-DSG1 antibody values of 20 IU/mL or higher and/or anti-DSG3 antibody values of 130 IU/mL or higher (P = .01). A PDAI score of 45 or higher defining severe pemphigus and/or persistent anti-DSG1 antibody values of 20 IU/mL or higher and/or anti-DSG3 antibody values of 130 IU/mL or higher at month 3 provided a positive predictive value of 50% (95% CI, 27%-73%) and a negative predictive value of 94% (95% CI, 73%-100%) for the occurrence of relapse after rituximab. CONCLUSIONS AND RELEVANCE The findings suggest that initial PDAI score and changes in anti-DSG antibody values after the initial cycle of rituximab might help differentiate a subgroup of patients with high risk of relapse who might benefit from maintenance rituximab infusion at month 6 from a subgroup of patients with low risk of relapse who do not need early maintenance therapy. TRIAL REGISTRATION NCT00784589
Fichier principal
Vignette du fichier
jamadermatology_mignard_2020_oi_200010.pdf (353.74 Ko) Télécharger le fichier
Origin : Publisher files allowed on an open archive

Dates and versions

hal-03434339 , version 1 (18-11-2021)

Identifiers

Cite

Claire Mignard, Maud Maho-Vaillant, Marie-Laure Golinski, Pierre Balayé, Catherine Prost-Squarcioni, et al.. Factors Associated With Short-term Relapse in Patients With Pemphigus Who Receive Rituximab as First-line Therapy. JAMA Dermatology, 2020, 156, ⟨10.1001/jamadermatol.2020.0290⟩. ⟨hal-03434339⟩

Collections

URCA IRMAIC
14 View
38 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More